#lung cancer

First-Line Immunotherapy Combo Slows Lung Cancer Progression

Precision medicine matches patients with the treatments most likely to work for them.

Immunotherapy worked better than chemotherapy as first-line treatment for people with a favorable biomarker.

New drug targets RET mutations in multiple cancer types.

Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018.

Join over 1,000 dedicated CancerCare supporters for the 16th Annual Lung Cancer Walk for Hope.

The combination led to better outcomes for people newly diagnosed with advanced non-small-cell lung cancer.

Efficacy of novel approach in human lung, skin, colon, pancreatic cancers in lab experiments prompts rapid move toward clinical trial.

Immunotherapy approved for previously untreated patients with nonsquamous non-small-cell lung cancer.

Responses were durable for at least six months in 77% of responders.

First new treatment in two decades for uncommon type of lung cancer.

By 2030, women around the world will be more likely to die of lung cancer than breast cancer.